COMPOSICIONES UTILIZABLES PARA REGULAR LA ACTIVIDAD DE LA PARQUINA

Polipéptido que interactúa con la parquina que presenta en toda su longitud una identidad de al menos 95% con la secuencia SEQ ID Nº: 2. An isolated human Parkin-Associated Protein 1 (PAP1) protein, is new. Independent claims are also included for the following: (i) a polypeptide comprising the 344...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: BRICE, ALEXIS, PRADES, CATHERINE, KOUTNIKOVA, HANA, PRADIER, LAURENT, ARNOULD-REGUIGNE, ISABELLE, FOURNIER, ALAIN
Format: Patent
Sprache:spa
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Polipéptido que interactúa con la parquina que presenta en toda su longitud una identidad de al menos 95% con la secuencia SEQ ID Nº: 2. An isolated human Parkin-Associated Protein 1 (PAP1) protein, is new. Independent claims are also included for the following: (i) a polypeptide comprising the 344 amino acid sequence fully defined in the specification (I), or its derivative or fragment; (ii) a composition capable of at least partly modifying interaction between PAP1 protein or its homologue and Parkin; (iii) a nucleic acid encoding the above polypeptide or composition (iv) a nucleic acid, particularly a probe, capable of hybridizing with the above nucleic acid; (v) a vector comprising the above nucleic acid; (vi) a recombinant disarmed virus comprising the above nucleic acid; (vii) a nucleic acid having one of the 19-26 nucleotide (nt) sequences fully defined in the specification; (viii) an antibody or its fragment or derivative directed against the above composition, preferably one that recognizes the above polypeptide; (ix) a non-peptide or not naturally exclusively peptide composition likely to at least partially modulate interaction between PAP1 protein or its homologue and Parkin; (x) selecting or characterizing active molecules, comprising selecting molecules capable of binding to sequence I, or the 156, 610 or 313 amino acid sequence fully defined in the specification, or their fragment; (xi) producing the above peptide composition, comprising culturing cells containing the nucleic acid of (iii), or the above vector under expression conditions and recovering the expressed peptide; (xii) a cell containing the nucleic acid of (iii) or the above vector; and (xiii) a non-human mammal whose cells comprise the nucleic acid of (iii). ACTIVITY : Antiparkinsonian. MECHANISM OF ACTION : None given.